|
Orthologous residues
|
|
CBX3 (human): S93‑p, CBX3 iso3 (human): ‑, CBX3 (mouse): S93‑p, CBX3 (rat): S93‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
phospho-antibody
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
hamster, human
|
|
Enzymes shown to modify site in vitro:
|
|
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
PKACa (human)
|
antisense inhibition of upstream enzyme, pharmacological inhibitor of upstream enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
isoproterenol
|
|
|
|
increase
|
|
|
staurosporine
|
|
|
|
decrease
|
|
|
forskolin, staurosporine
|
|
|
|
increase
|
|
|
KT5720
|
|
|
|
decrease
|
|
|
siRNA
|
|
|
|
decrease
|
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
molecular association, regulation
|
|
Modification regulates interactions with:
|
|
Interacting molecule
|
Interacting domains
|
Effect
|
Consequences (function)
|
Consequences (process)
|
Detection assays
|
|
Ku70 (human)
|
|
Not reported
|
|
|
co-immunoprecipitation, microscopy-colocalization
|
|
|
Comments:
may regulate gene expression and silencing
|
